Allogenic bone marrow transplantation from a related donor in China typically costs from $60,000 to $70,000. The total price depends on the intensity of the conditioning regimen, duration of isolation in HEPA-filtered units, and management of potential graft-versus-host disease. In the US, this procedure costs $400,000 on average. Standard medical packages generally include cell harvesting, chemotherapy, and approximately 30 to 60 days of inpatient care.
Bookimed Expert Insight. Specialized departments in Shanghai offer highly competitive rates for complex hematology. Shanghai Tongji Hospital reports performing over 1,500 infusions. Their programs for lymphoma and leukemia typically run about $65,000. Choosing university-affiliated tertiary centers provides access to multidisciplinary teams. These teams manage complex cases without the extreme price tags found in Western private facilities.
| China | Turkey | Austria | |
| Allogenic bone marrow transplantation from a related donor | from $60,000 | from $54,500 | ≈ $95,000 |
No hidden fees – just official clinic prices. Pay at the clinic for Allogenic bone marrow transplantation from a related donor upon arrival and use a flexible installment plan if needed.
Bookimed is committed to your safety. We only work with medical institutions that maintain high international standards in Allogenic bone marrow transplantation from a related donor and have the necessary licenses to serve international patients worldwide.
Bookimed offers free expert assistance. A personal medical coordinator supports you before, during, and after your treatment, solving any issues. You're never alone on your Allogenic bone marrow transplantation from a related donor journey.
Day 1
Day 2 to 3
Day 4
Day 5
Day 6 to Week 2
Week 3 to 8
Week 8 onwards
Please note that this schedule may vary depending on individual patient conditions and recovery progress.
Chief physician and professor. Grade 1 Expert at the Cancer Center, West China Hospital, Sichuan University (ranked No. 2 in China). Completed a postdoctoral fellowship in interventional radiology at the Chinese PLA General Hospital. Leads multidisciplinary team (MDT) care for complex tumors. Expert in minimally invasive interventional oncology for liver, lung, and pancreatic cancers.
Accreditations: Council Member, WATA. Member of CACA and CMDA committees on intervention, ablation, radioactive seeds, and pain. In 2023, inaugural director member, Palliative Care Committee, Sichuan MDA. Editorial board member of the Chinese Journal of Interventional Imaging and Therapy. Editorial board member of the Chinese Journal of Pain Medicine.
Leads 2 provincial S&T projects and 2 NSFC projects. Has 40+ papers, with 30+ as first or corresponding author. Highest impact factor: 10.73. Hepatocellular carcinoma (HCC) cohort: TACE + lenvatinib vs TACE + sorafenib. OS 18.97 vs 10.77 months. PFS 10.6 vs 5.4 months. ORR 66.8% vs 33.3%.
Professor Xiao Yueyong is Chief Physician in the Department of Radiological Diagnosis at the Chinese PLA General Hospital. He is a leading expert in minimally invasive interventional oncology. He serves as the inaugural President of WATA (2025–). He is President of the International (2020–) and Asian (2012–) Societies of Cryotherapy. He is also Deputy Head of the NHC Expert Group on tumour ablation regulations (2009–).
He has performed over 100,000 CT/MRI‑guided minimally invasive procedures. His work covers chemical ablation, RFA, MWA, cryoablation, and NanoKnife (IRE). He introduced and advanced NanoKnife ablation in China. He led the first national standards for tumour cryoablation and NanoKnife.
Honors include the National Special Contribution Award (Lifetime Honorary). He received First Prize from the Chinese Medicine Education Association (2021). He received two Second Prizes for Military Medical Achievements (2016, 2018) and two Second Prizes from the China Anti‑Cancer Association (2019, 2022). He was named Asian Ablation Master. His research record includes 13 Chinese patents. He is the principal investigator for four NSFC projects and one MOST subject. He has published over 200 papers, with over 110 as first or corresponding author and over 40 in SCI journals. He has led over 10 ablation guidelines or consensus statements.
This procedure involves transferring healthy stem cells from a closely matched family member to replace damaged bone marrow in patients with certain diseases.